Dallas, Texas – April 18, 2017 – Puration, Inc. (USOTC: PURA) today announced the Company has filed its 2016 annual financial report. The report includes the first revenue since the Company launched its cannabis extraction operations. The Company has published a $3 million revenue forecast plan anticipated from sales to be generated from its first cannabis infused beverage contracts. The first beverages have been launched. EVERx CBD Infused Bottled Sports Water and EVERx Alkaline Bottles Sports Water were launched at Arnold Schwarzenegger’s recent Annual Arnold Sports Festival. The EVERx Products will again be featured as part of North American Cannabis Holdings’, (USOTC: USMJ) AmeriCanna Cafe restaurant launch at the Southwest Cannabis Conference and Expo in Fort Worth, Texas later this week. The first PURA sales realized just before year end 2016 making their way onto the 2016 financial report amounted to $100,000.
PURA operates the NCM Biotech, Inc. patent for cannabis extraction to produce the finest cannabis extracts for infusion into food and beverages. NCM Biotech has licensed to PURA the right to utilize NCM Biotech’s patented cannabis extraction process to produce cannabis extracts for infusion into recreational, fitness wellness, alternative medicine and beauty products. NCM Biotech exclusively owns U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” The license of the process to PURA is the first and only license NCM Biotech has executed.
To learn more about Puration: purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Brian Shibley, CEO